At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 85 enrolled
Drug / intervention
CTN SR +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Sep 11, 2015·Updated Nov 11, 2021
In Brief
A Phase 2 clinical trial evaluating CTN SR and Matching placebo for Attention Deficit Disorder With Hyperactivity. Completed, enrolled 85 participants across 4 sites.
Detailed Summary
This was a Phase 2b, randomized, double-blind, multicenter, 2-period, 2-treatment, crossover study to evaluate safety and efficacy of CTN SR compared with placebo in adults with ADHD. Efficacy was also evaluated in the subgroup of adults with ADHD treated with a target CTN SR dose of 400 mg/day.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedSep 2015
Primary CompletionJun 2016
TodayJul 2026
First PostedSep 11, 2015
Enrollment StartAug 3, 2015
Primary CompletionJun 4, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.8 years ago
Interventions
CTN SRdrug
CTN SR tablets, daily, Orally.
Matching placebodrug
Matching-placebo tablets daily, orally.